Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 10/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12747760 | 0.99 | LTB4R (0.43) | LTB4RCYP4F2CYP4A11CYP1A2CYP2C9 | |
| SCHEMBL12747693 | 0.84 | KCNH2 (0.42) | LTB4RCYP4F2CYP4A11PPARAKCNH2 | |
| SCHEMBL12747699 | 0.84 | KCNH2 (0.42) | LTB4RCYP4F2CYP4A11PPARAKCNH2 | |
| SCHEMBL12747752 | 0.84 | KCNH2 (0.36) | LTB4RCYP4F2CYP4A11CYP1A2KCNH2 | |
| SCHEMBL12747761 | 0.83 | KCNH2 (0.38) | LTB4RCYP4F2CYP4A11KCNH2 | |
| SCHEMBL12747870 | 0.83 | KCNH2 (0.38) | LTB4RKCNH2 | |
| SCHEMBL12747813 | 0.81 | CYP4F2 (0.38) | LTB4RCYP4F2CYP4A11CYP1A2CYP2C9 | |
| SCHEMBL12747900 | 0.81 | DAGLA (0.38) | LTB4RPPARAKCNH2 | |
| SCHEMBL12747713 | 0.78 | LTB4R (0.56) | LTB4RPPARA | |
| SCHEMBL12747734 | 0.77 | LTB4R (0.57) | LTB4RPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480554-B1 | MACROCYCLIC INHIBITORS OF JAK | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8318764-B2 | Macrocyclic inhibitors of JAK | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318764-B2 | Macrocyclic inhibitors of JAK | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| WO-2011033053-A1 | MACROCYCLIC INHIBITORS OF JAK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
| US-20110071179-A1 | MACROCYCLIC INHIBITORS OF JAK | JAHANGIR ALAM | 2011-03-24 | — | — | US | disclosed |
| US-20110071179-A1 | MACROCYCLIC INHIBITORS OF JAK | JAHANGIR ALAM | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071179-A1 | MACROCYCLIC INHIBITORS OF JAK | JAK2, JAK1, JAK3 | LTB4R 927/4885CYP4F2 1777/4885CYP4A11 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.